DrugPatentWatch Database Preview

Takeda Pharms Usa Company Profile

TAKEDA PHARMS USA has seventeen approved drugs.

There are eighty-seven US patents protecting TAKEDA PHARMS USA drugs.

There are one thousand one hundred and one patent family members on TAKEDA PHARMS USA drugs in fifty-eight countries and ninety-eight supplementary protection certificates in fifteen countries.

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-005	Mar 27, 2012		DISCN	No	No	7,414,105	➤ Sign Up	Y	Y		➤ Sign Up
Takeda Pharms Usa	COLCRYS	colchicine	TABLET;ORAL	022352-001	Jul 29, 2009		RX	Yes	Yes	8,097,655	➤ Sign Up				➤ Sign Up
Takeda Pharms Usa	KAZANO	alogliptin benzoate; metformin hydrochloride	TABLET;ORAL	203414-001	Jan 25, 2013		RX	Yes	No	8,288,539	➤ Sign Up		Y		➤ Sign Up
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-002	Jan 25, 2013		RX	Yes	No	6,890,898	➤ Sign Up				➤ Sign Up
Takeda Pharms Usa	OMONTYS PRESERVATIVE FREE	peginesatide acetate	SOLUTION;INTRAVENOUS, SUBCUTANEOUS	202799-005	Mar 27, 2012		DISCN	No	No	7,084,245	➤ Sign Up	Y	Y		➤ Sign Up
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-002	Jan 30, 2009	AB	RX	Yes	Yes	9,011,926	➤ Sign Up	Y			➤ Sign Up
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009		RX	Yes	No	9,233,103	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	NESINA	alogliptin benzoate	TABLET;ORAL	022271-001	Jan 25, 2013	6,303,661	➤ Sign Up
Takeda Pharms Usa	DUETACT	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	021925-001	Jul 28, 2006	4,687,777	➤ Sign Up
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-004	Jan 25, 2013	7,459,428	➤ Sign Up
Takeda Pharms Usa	PREVACID	lansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	021428-001	Aug 30, 2002	6,749,864	➤ Sign Up
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-005	Jan 25, 2013	6,890,898	➤ Sign Up
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-003	Jan 25, 2013	6,271,243	➤ Sign Up
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-004	Jan 25, 2013	6,303,661	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	30 mg/2 mg and 30 mg/4 mg	➤ Subscribe	2009-12-22
➤ Subscribe	Tablets	6.25 mg, 12.5 mg and 25 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Tablets	5 mg, 10 mg, 15 mgand 20 mg	➤ Subscribe	2017-10-02
➤ Subscribe	Delayed-release Pellets/Capsul	15 mg and 30 mg	➤ Subscribe	2005-12-05
➤ Subscribe	Capsule	60 mg	➤ Subscribe	2010-08-25
➤ Subscribe	Extended-release Tablets	15 mg/1000 mg and 30 mg/1000 mg	➤ Subscribe	2011-09-23
➤ Subscribe	Tablets	0.6 mg	➤ Subscribe	2011-12-23
➤ Subscribe	Tablets	12.5 mg/500 mg and 12.5 mg/1000 mg	➤ Subscribe	2017-01-25
➤ Subscribe	Tablets	8 mg	➤ Subscribe	2009-07-22
➤ Subscribe	Tablets	40 mg and 80 mg	➤ Subscribe	2013-02-13
➤ Subscribe	Delayed-release Orally Disinte	15 mg and 30 mg	➤ Subscribe	2006-12-27
➤ Subscribe	Delayed-release Capsule	30 mg	➤ Subscribe	2010-11-30
➤ Subscribe	Tablets	15 mg/500 mg and 15 mg/850 mg	➤ Subscribe	2008-03-06

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
European Patent Office	2044043	➤ Sign Up
China	1310613	➤ Sign Up
World Intellectual Property Organization (WIPO)	9732871	➤ Sign Up
Croatia	P20161121	➤ Sign Up
Canada	2737851	➤ Sign Up
Japan	2007530439	➤ Sign Up
World Intellectual Property Organization (WIPO)	2009025958	➤ Sign Up
Country	Document Number	Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
14/012	Ireland	➤ Sign Up	PRODUCT NAME: ALOGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919
128	Luxembourg	➤ Sign Up	PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
2014 00037	Denmark	➤ Sign Up	PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116
/2010	Austria	➤ Sign Up	PRODUCT NAME: FEBUXOSTAT IN DER KRISTALLFORM A; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
1	Finland	➤ Sign Up
2014013,C1436271	Lithuania	➤ Sign Up	PRODUCT NAME: VORTIOKSETINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA RUGSTIES PRISIJUNGIMO DRUSKA; REGISTRATION NO/DATE: EU/1/13/891 20131218
2014 00030	Denmark	➤ Sign Up	PRODUCT NAME: VORTIOXETIN ELLER FARMACEUTISK ACCEPTABLE SYREADDITIONSSALTE DERAF, HERUNDER VORTIOXETINHYDROBROMID; REG. NO/DATE: EU/1/13/891 20131218
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.